非侵入性神经调节心律失常的非侵入性神经调节
Johnathon Rast1, Daniel Sohinki1, Alexander Warner1
1Medical College of Georgia, Augusta, GA, USA.
The Journal of innovations in cardiac rhythm management
|March 6, 2024
概括
调节心脏自主神经系统 (CANS) 的非侵入性策略在治疗心房动和心室失律方面表现有前途. 这些低风险的方法为管理复杂的心脏疾病提供了潜在的辅助疗法.
科学领域:
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
- 医疗技术 医疗技术 医学技术
背景情况:
- 心脏自主神经系统 (CANS) 功能障碍与各种心律失常有关.
- 侵入性CANS调制,就像同情性消神一样,已被确立用于治疗心律失常,如心室高心率风暴.
- 非侵入性策略正在成为一种低风险的辅助治疗方法.
研究的目的:
- 审查目前用于调节CANS的非侵入性技术.
- 评估使用这些技术抑制心房动和心室心律失常的证据.
- 为未来的研究和临床应用提供基于证据的概述.
主要方法:
- 对当前非侵入性CANS调制技术的文献综述.
- 对研究这些技术在抑制心律失常方面的有效性进行分析.
- 对心房动和心室节律失常的技术方法的基于证据的评估.
主要成果:
- 非侵入性CANS调制技术正在为心律失常管理进行研究.
- 这些方法提供了一种潜在的更安全的替代方案或对侵入性手术的补充.
- 证据支持探索这些技术用于心房动和心室节律失常.
结论:
- 对CANS的非侵入性调制代表了在心律失常治疗中的一个有希望的前沿.
- 需要进一步的研究才能充分确定这些技术的有效性和安全性.
- 这些方法可能会扩大心房动和心室心律不整的患者的治疗选择.
相关概念视频
Mechanism of Cardiac Arrhythmias
919
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
919
Disturbances in Heart Rhythm
952
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
952
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
994
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
994
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832


